Human papillomavirus vaccines: A new challenge for pediatricians;Vacuna frente al virus del papiloma humano: Un nuevo reto para el pediatra

Anales de Pediatria

Volumn 65, Issue 5, 2006, Pages 461-469

  Martinon Torres F ^a,b   Bernaola Iturbe, E ^a,c   Gimenez Sanchez F ^a   Baca Cots, M ^a   De Juan Martin F ^a   Diez Domingo J ^a   Garces Sanchez M ^a   Gomez Campdera J A ^a   Picazo, J J ^a   Pineda Solas, V ^a  

^a Hospital Clínico   (Spain)

^b European Advisory Board on Human Papillomavirus ^*

^c NONE   (Spain)

Author keywords

Cervical cancer; Genital warts; Human papillomavirus; Pediatrics; Vaccine

Indexed keywords

WART VIRUS VACCINE;

CLINICAL PRACTICE; DISEASE ASSOCIATION; HUMAN; IMMUNIZATION; INFECTION PREVENTION; INFECTION RISK; NONHUMAN; PEDIATRICIAN; PREVALENCE; REVIEW; UTERINE CERVIX CANCER; VIRUS INFECTION; VIRUS TRANSMISSION; WART VIRUS;

EID: 33845652110     PISSN: 16954033     EISSN: None     Source Type: Journal    
DOI: 10.1157/13094258     Document Type: Article

References (61)

1. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine. 2006;24 Suppl 1:1-15.
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189: 12-9.
3. Herrero R, Castellsague X, Pawlita M, Lissowska J, Kee F, Balaram P, et al. Human papillomavirus and oral cancer: The International Agency for Research on Cancer multicenter study. J Natl Cancer Inst. 2003;95:1772-83.
4. Munoz N. Human papillomavirus and cancer: The epidemiological evidence. J Clin Virol. 2000;19:1-5.
5. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244-65.
6. Von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol. 2001;11:598-603; quiz 604.
7. Jayasinghe YL, Garland SM. Genital warts in children: What do they mean? Arch Dis Child. 2006 (pendiente de publicación).
8. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: Incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157:218-26.
9. Tarkowski TA, Koumans EH, Sawyer M, Pierce A, Black CM, Papp JR, et al. Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population. J Infect Dis. 2004;189:46-50.
10. Shew ML, Fortenberry JD. VPH infection in adolescents: Natural history, complications, and indicators for viral typing. Semin Pediatr Infect Dis. 2005;16:168-74.
11. Brown DR, Shew ML, Qadadri B, Neptune N, Vargas M, Tu W, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis. 2005;191:182-92.
12. Collins S, Mazloomzadeh S, Winter H, Blomfield P, Bailey A, Young LS, et al. High incidence of cervical human papillomavirus infection in women during their first sexual relationship. Bjog. 2002;109:96-8.
13. Villa LL. Prophylactic HPV vaccines: Reducing the burden of HPV-related diseases. Vaccine. 2006;24 Suppl 1:23-8.
14. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest. 2006;116:1167-73.
15. Stanley MA. Human papillomavirus vaccines. Rev Med Virol. 2006;16:139-49.
16. Muñoz N, Bosch FX, De Sanjosé S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518-27.
17. Melsheimer P, Kaul S, Dobeck S, Bastert G. Immunocytochemical detection of HPV high-risk type L1 capsid proteins in LSIL and HSIL as compared with detection of HPV L1 DNA. Acta Cytol. 2003;47:124-8.
18. WHO vaccine report. The current status of development of prophylactic vaccines against human papillomavirus infection. Report of a technical meeting. World Health Organization; 1999. Disponible en: http://www.who.int/ vaccine_research/documents/en/PVH1.pdf (última consulta 16-7-2006).
19. Zur Hausen H. Papillomavirus infections-a major cause of human cancers. Biochim Biophys Acta. 1996;1288:F55-F78.
20. Linnehan MJ, Groce NE. Counseling and educational interventions for women with genital human papillomavirus infection. AIDS Patient Care STDS. 2000;14:439-45.
21. Sinal SH, Woods CR. Human papillomavirus infections of the genital and respiratory tracts in young children. Semin Pediatr Infect Dis. 2005;16:306-16.
22. Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med. 2006;354: 2645-54.
23. Bleeker MC, Berkhof J, Hogewoning CJ, Voorhorst FJ, Van den Brule AJ, Starink TM, et al. HPV type concordance in sexual couples determines the effect of condoms on regression of flat penile lesions. Br J Cancer. 2005;92:1388-92.
24. Hogewoning CJ, Bleeker MC, Van den Brule AJ, Voorhorst FJ, Snijders PJ, Berkhof J, et al. Condom use promotes regression of cervical intraepithelial neoplasia and clearance of human papillomavirus: A randomized clinical trial. Int J Cancer. 2003; 107:811-6.
25. Kahn JA, Rosenthal SL, Succop PA, Ho GY, Burk RD. The interval between menarche and age of first sexual intercourse as a risk factor for subsequent HPV infection in adolescent and young adult women. J Pediatr. 2002;141:718-23.
26. Kahn JA, Rosenthal SL, Succop PA, Ho GY, Burk RD. Mediators of the association between age of first sexual intercourse and subsequent human papillomavirus infection. Pediatrics. 2002; 109:E5.
27. Burk RD, Ho GY, Beardsley L, Lempa M, Peters M, Bierman R. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis. 1996;174:679-89.
28. Burk RD, Kelly P, Feldman J, Bromberg J, Vermund SH, De-Hovitz JA, et al. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sex Transm Dis. 1996;23:333-41.
29. Minkoff H, Feldman JG, Strickler HD, Watts DH, Bacon MC, Levine A, et al. Relationship between smoking and human papillomavirus infections in HIV-infected and -uninfected women. J Infect Dis. 2004;189:1821-8.
30. García-Closas R, Castellsague X, Bosch X, Gonzalez CA. The role of diet and nutrition in cervical carcinogenesis: A review of recent evidence. Int J Cancer. 2005;117:629-37.
31. Maciag PC, Schlecht NF, Souza PS, Rohan TE, Franco EL, Villa LL. Polymorphisms of the human leukocyte antigen DRB1 and DQB1 genes and the natural history of human papillomavirus infection. J Infect Dis. 2002;186:164-72.
32. Stanley M. Immune responses to human papillomavirus. Vaccine. 2006;24 Suppl 1:16-22.
33. Nguyen HH, Broker TR, Chow LT, Álvarez RD, Vu HL, Andrasi J, et al. Immune responses to human papillomavirus in genital tract of women with cervical cancer. Gynecol Oncol. 2005;96:452-61.
34. Kadish AS, Timmins P, Wang Y, Ho GY, Burk RD, Ketz J, et al. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide. Cancer Epidemiol Biomarkers Prev. 2002;11:483-8.
35. Snijders PJ, Steenbergen RD, Heideman DA, Meijer CJ. HPV-mediated cervical carcinogenesis: Concepts and clinical implications. J Pathol. 2006;208:152-64.
36. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomized controlled trial. Lancet. 2004;364:1757-65.
37. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: A randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271-8.
38. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, et al. Efficacy of human papillamavirus-16 vaccine to prevent cervical intraepithelial neoplasia: A randomized controlled trial. Obstet Gynecol. 2006;107:18-27.
39. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4-5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomized control trial. Lancet. 2006;367:1247.
40. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Álvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002;347:1645-51.
41. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ, et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst. 2001;93:284-92.
42. Fife KH, Wheeler CM, Koutsky LA, Barr E, Brown DR, Schiff MA, et al. Dose-ranging studies of the safety and immunogenicity of human papillomavirus type 11 and type 16 virus-like particle candidate vaccines in young healthy women. Vaccine. 2004;22:2943-52.
43. Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA, et al. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis. 2001;183:1485-93.
44. Greer CE, Wheeler CM, Ladner MB, Beutner K, Coyne MY, Liang H, et al. Human papillomavirus (PVH) type distribution and serological response to PVH type 6 virus-like particles in patients with genital warts. J Clin Microbiol. 1995;33:2058-63.
45. Villa LL, Ault KA, Giuliano AR, Costa RL, Petta CA, Andrade RP, et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine. 2006;24:5571-83.
46. Ficha técnica del Gardasil® [Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine]. Disponible en: http://www.merck. com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf (última consulta 15-07-2006).
47. Informe de la Food and Drug Administration (FDA) de Estados Unidos sobre Gardasil®: Disponible en: http://www.fda.gov/ cber/products/hpvmer060806.htm (última consulta 15-07-2006).
48. HPV vaccine. Advisory Committee on Immunization Practices. Centers for Disease Control and Prevention. Disponible en: http://www.cdc.gov/nip/vaccine/ hpv/default.htm (última consulta 15-07-2006).
49. Dubin G. Enhanced immunogenicity of a candidate human papillomavirus (HPV) 16/18 L1 virus like particle (VLP) vaccine with novel AS04 adjuvant in preteens/adolescents. Presentado en: 45th Annual international Conference on Antimicrobial Agents and Chemotherapy (ICAAC). December 2005, Washington, USA.
50. Muñoz N. A Review of the initial Phase III Clinical Data for the Quadrivalent Human Papillomavirus Vaccine, 6th International Multidisciplinary Congress of the European Research Organization on Genital Infection and Neoplasia. Presentado en: EUROGIN, April 2006, Paris.
51. Barnabas RV, Laukkanen P, Koskela P, Kontula O, Lehtinen M, Garnett GP. Epidemiology of HPV 16 and Cervical Cancer in Finland and the Potential Impact of Vaccination: Mathematical Modelling Analyses. PLoS Med. 2006;3(5):e138.
52. Partridge JM, Koutsky LA, Genital human papillomavirus infection in men. Lancet Infect Dis. 2006;6:21-31.
53. Kahn JA, Zimet GD, Bernstein DI, Riedesel JM, Lan D, Huang B, et al. Pediatricians' intention to administer human papillomavirus vaccine: The role of practice characteristics, knowledge, and attitudes. J Adolesc Health. 2005;37:502-10.
54. Kahn JA, Bernstein DI. Human papillomavirus vaccines and adolescents. Curr Opin Obstet Gynecol. 2005;17:476-82.
55. Olshen E, Woods ER, Austin SB, Luskin M, Bauchner H. Parental acceptance of the human papillomavirus vaccine. J Adolesc Health. 2005;37:248-51.
56. Zimet GD, Mays RM, Sturm LA, Ravert AA, Perkins SM, Juliar BE. Parental attitudes about sexually transmitted infection vaccination for their adolescent children. Arch Pediatr Adolesc Med. 2005;159:132-7.
57. Dempsey AF, Zimet GD, Davis RL, Koutsky L. Factors that are associated with parental acceptance of human papillomavirus vaccines: A randomized intervention study of written information about PVH. Pediatrics. 2006;117:1486-93.
58. Riedesel JM, Rosenthal SL, Zimet GD, Bernstein DI, Huang B, Lan D, et al. Attitudes about human papillomavirus vaccine among family physicians. J Pediatr Adolesc Gynecol. 2005;18:391-8.
59. Kadish AS, Einstein MH. Vaccine strategies for human papillomavirus- associated cancers. Curr Opin Oncol. 2005;17: 456-61.
60. Zimet GD, Perkins SM, Sturm IA, Bair RM, Juliar BE, Mays RM. Predictors of STI vaccine acceptability among parents and their adolescent children. J Adolesc Health. 2005;37:179-86.
61. Mays RM, Sturm LA, Zimet GD. Parental perspectives on vaccinating children against sexually transmitted infections. Soc Sci Med. 2004;58:1405-13.